CDR-FR Peptides

  • Xiao-Qing QiuEmail author
Part of the Springer Protocols Handbooks book series (SPH)

The non-immunogenic antigen binder has emerged as an important component in the research of cell recognition and targeting with the high degree of specificity inherited from prototypical antibody (Hoogenboom 2005; Holliger and Hudson 2005; Hu et al. 1996; Olafsen et al. 2004; Shahied et al. 2004). However, the optimal binding interfaces of the antigen binders remained to be defined though various entities had been proposed (Hoogenboom 2005; Holliger and Hudson 2005; Hu et al. 1996; Olafsen et al. 2004; Shahied et al. 2004; Cortez-Retamozo et al. 2002; Genst et al. 2004). In a classic antibody, antigen recognition is accomplished with the multiple noncovalent forces, which are synergistically produced by three complementarity determining regions (CDRs) of VH and other three CDRs of VL domains (Laune et al. 1997; Aburatani et al. 2002; Ewert et al. 2003; Borg et al. 2005; Hunt et al. 2005; Rothlisberger et al. 2005). The synergic interactions of VH and VL domains, inevitably, comprise a substantial component of the multiple noncovalent forces. However, the contribution of such synergic interactions to antigen recognition by an antibody has not yet been thoroughly investigated (Hu et al. 1996; Olafsen et al. 2004; Shahied et al. 2004; Ewert et al. 2003; Borg et al. 2005). On the other hand, the energetic studies of CDRs in the lymphocyte receptor had indicated that in the variable domains each CDR loop may play different hierarchical roles for antigen recognition (Borg et al. 2005). Therefore, the “cross-reactivity” of CDRs in VH and VL domains should not be neglected in the composition of non-immunogenic antigen binder. To accommodate the “cross-reactivity” between the structural elements of heavy and light variable domains, we assumed that one VH CDR and one VL CDR sequentially linked with a framework region (FR) that linked CDRs would consist of a 28-residue antigen binder as a rational non-immunogenic antigen-binding interface model with the minimized structural form (Laune et al. 1997; Aburatani et al. 2002; Ewert et al. 2003).


Synergic Interaction Variable Domain Antigen Binder Antigen Recognition Complementarity Determine Region 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Aburatani T, Ueda H, Nagamune T (2002) Importance of a CDR H3 basal residue in VH/VL interaction of human antibodies. J Biochem 132:775–785PubMedCrossRefGoogle Scholar
  2. Adams GP et al (2001) High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. Cancer Res 61:4750–4755PubMedGoogle Scholar
  3. Borg NA et al (2005) The CDR3 regions of an immunodominant T cell receptor dictate the ‘energetic landscape’ of peptide-MHC recognition. Nat Immunol 6:171–180PubMedCrossRefGoogle Scholar
  4. Carter PJ (2006) Potent antibody therapeutics by design. Nat Rev Immunol 6:343–357PubMedCrossRefGoogle Scholar
  5. Casset F et al (2003) A peptide mimetic of an anti-CD4 monoclonal antibody by rational design. Biochem Biophys Res Commun 307:198–205PubMedCrossRefGoogle Scholar
  6. Cortez-Retamozo V et al (2002) Effeicient tumor targeting by single-domain antibody fragments of camels. Int J Cancer 98:456–462PubMedCrossRefGoogle Scholar
  7. Ewert S, Huber T, Honegger A, Plückthun A (2003) Biophysical properties of human antibody variable domains. J Mol Biol 325:531–553PubMedCrossRefGoogle Scholar
  8. Fujimori K, Covell DG, Fletcher JE, Weinstein JN (1989) Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab’)2, and Fab in tumors. Cancer Res 49:5656–5663PubMedGoogle Scholar
  9. Genst ED et al (2004) Chemical basis for the affinity maturation of a camel single domain antibody. J Biol Chem 279:53593–53601PubMedCrossRefGoogle Scholar
  10. Heap CJ et al (2005) Analysis of a 17-amino acid residue, virus-neutralizing microantibody. J Gen Virol 86:1791–1800PubMedCrossRefGoogle Scholar
  11. Holliger P, Hudson P (2005) Engineered antibody fragments and the rise of single domains. Nat biotechnol 23:1126–1136PubMedCrossRefGoogle Scholar
  12. Hoogenboom HR (2005) Selecting and screening recombinant antibody libraries. Nat biotechnol 23:1105–1116PubMedCrossRefGoogle Scholar
  13. Hu S et al (1996) Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 56:3055–3061PubMedGoogle Scholar
  14. Hunt J et al (2005) Disulfide linkage controls the affinity and stoichiometry of IgE Fc{epsilon}3–4 binding to Fc{epsilon}RI. J Biol Chem 17:16808–16814CrossRefGoogle Scholar
  15. Laune D et al (1997) Systematic exploration of the antigen binding activity of synthetic peptides isolated from the variable regions of immunoglobulins. J Biol Chem 272:30937–30944PubMedCrossRefGoogle Scholar
  16. Midelfort KS et al (2004) Substantial energetic improvement with minimal structural perturbation in a high affinity mutant antibody. J Mol Biol 343:685–701PubMedCrossRefGoogle Scholar
  17. Olafsen T et al (2004) Characterization of engineered anti-p185HER-2 (ScFv-CH3)2 fragments (minibodies) for tumor targeting. Protein Eng Des Sel 17:315–323PubMedCrossRefGoogle Scholar
  18. Qin W et al (2006) Fusion protein of CDR mimetic peptide with Fc inhibit TNF-α induced cytotoxicity. Mol Immunol 43:660–666PubMedCrossRefGoogle Scholar
  19. Rothlisberger D, Honegger A, Pluckthun A (2005) Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability. J Mol Biol 347:773–789PubMedCrossRefGoogle Scholar
  20. Shahied LS et al (2004) Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. J Biol Chem 279:53907–53914PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  1. 1.Laboratory of Biomembrane and Membrane ProteinsWest China Hospital, Sichuan UniversityChengduPeople’s Republic of China

Personalised recommendations